Rapid and body weight-independent improvement of endothelial and high-density lipoprotein function after Roux-en-Y gastric bypass role of glucagon-like peptide-1

Circulation

Volumn 131, Issue 10, 2015, Pages 871-881

  Osto, Elena ^a   Doytcheva, Petia ^a,b   Corteville, Caroline ^b   Bueter, Marco ^a   Dörig, Claudia ^b   Stivala, Simona ^a   Buhmann, Helena ^b   Colin, Sophie ^d   Rohrer, Lucia ^c   Hasballa, Reda ^c   Tailleux, Anne ^d   Wolfrum, Christian ^e   Tona, Francesco ^f   Manz, Jasmin ^a   Vetter, Diana ^a   Spliethoff, Kerstin ^b   Vanhoutte, Paul M ^g   Landmesser, Ulf ^a   Pattou, Francois ^h   Staels, Bart ^d   Matter, Christian M ^a   Lutz, Thomas A ^b   Lüscher, Thomas F ^a   more..

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIV LILLE   (France)

^e ETH ZURICH   (Switzerland)

^f UNIVERSITY OF PADOVA   (Italy)

^g UNIVERSITY OF HONG KONG   (Hong Kong)

^h LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Bariatric surgery; Endothelium; Glucagon like peptide 1; Lipoproteins; Nitric oxide; Obesity

Indexed keywords

BILE ACID; ENDOTHELIUM DERIVED RELAXING FACTOR; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; HIGH DENSITY LIPOPROTEIN; NITRIC OXIDE; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; ANTIOXIDANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BIOAVAILABILITY; BODY WEIGHT; CARDIOVASCULAR MORTALITY; CHOLESTEROL DIET; COMPARATIVE STUDY; CONTROLLED STUDY; DIET INDUCED OBESITY; DISEASE ASSOCIATION; ENDOTHELIUM CELL; ENZYME ACTIVATION; MALE; MORBID OBESITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; ROUX Y ANASTOMOSIS; STOMACH BYPASS; WEIGHT REDUCTION; ADULT; ADVERSE EFFECTS; ANIMAL; CASE CONTROL STUDY; CELL CULTURE; DISEASE MODEL; FEMALE; HUMAN; LIPID DIET; OBESITY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; WISTAR RAT;

ADULT; ANIMALS; ANTIOXIDANTS; BODY WEIGHT; CASE-CONTROL STUDIES; CELLS, CULTURED; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; FEMALE; GASTRIC BYPASS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; LIPOPROTEINS, HDL; MALE; NITRIC OXIDE; OBESITY; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84929429661     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.114.011791     Document Type: Article

References (47)

1. Poirier P, Cornier MA, Mazzone T, Stiles S, Cummings S, Klein S, McCullough PA, Ren Fielding C, Franklin BA; American Heart Association Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Bariatric surgery and cardiovascular risk factors: a scientific statement from the American Heart Association. Circulation. 2011;123:1683-1701. doi: 10.1161/CIR.0b013e3182149099.
2. Sansbury BE, Cummins TD, Tang Y, Hellmann J, Holden CR, Harbeson MA, Chen Y, Patel RP, Spite M, Bhatnagar A, Hill BG. Overexpression of endothelial nitric oxide synthase prevents diet-induced obesity and regulates adipocyte phenotype. Circ Res. 2012;111:1176-1189. doi: 10.1161/CIRCRESAHA.112.266395.
3. Mauricio MD, Aldasoro M, Ortega J, Vila JM. Endothelial dysfunction in morbid obesity. Curr Pharm Des. 2013;19:5718-5729.
4. Bays HE, Toth PP, Kris-Etherton PM, Abate N, Aronne LJ, Brown WV, Gonzalez-Campoy JM, Jones SR, Kumar R, La Forge R, Samuel VT. Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association. J Clin Lipidol. 2013;7:304-383. doi: 10.1016/j.jacl.2013.04.001.
5. Asztalos BF, Swarbrick MM, Schaefer EJ, Dallal GE, Horvath KV, Ai M, Stanhope KL, Austrheim-Smith I, Wolfe BM, Ali M, Havel PJ. Effects of weight loss, induced by gastric bypass surgery, on HDL remodeling in obese women. J Lipid Res. 2010;51:2405-2412. doi: 10.1194/jlr.P900015.
6. Sorrentino SA, Besler C, Rohrer L, Meyer M, Heinrich K, Bahlmann FH, Mueller M, Horváth T, Doerries C, Heinemann M, Flemmer S, Markowski A, Manes C, Bahr MJ, Haller H, von Eckardstein A, Drexler H, Landmesser U. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation. 2010;121:110-122. doi: 10.1161/CIRCULATIONAHA.108.836346.
7. Besler C, Heinrich K, Rohrer L, Doerries C, Riwanto M, Shih DM, Chroni A, Yonekawa K, Stein S, Schaefer N, Mueller M, Akhmedov A, Daniil G, Manes C, Templin C, Wyss C, Maier W, Tanner FC, Matter CM, Corti R, Furlong C, Lusis AJ, von Eckardstein A, Fogelman AM, Lüscher TF, Landmesser U. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest. 2011;121:2693-2708. doi: 10.1172/JCI42946.
8. Lüscher TF, Landmesser U, von Eckardstein A, Fogelman AM. High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target. Circ Res. 2014;114:171-182. doi: 10.1161/CIRCRESAHA.114.300935.
9. Raffaelli M, Guidone C, Callari C, Iaconelli A, Bellantone R, Mingrone G. Effect of gastric bypass versus diet on cardiovascular risk factors. Ann Surg. 2014;259:694-699. doi: 10.1097/SLA.0b013e31829d6989.
10. Ikramuddin S, Korner J, Lee WJ, Connett JE, Inabnet WB, Billington CJ, Thomas AJ, Leslie DB, Chong K, Jeffery RW, Ahmed L, Vella A, Chuang LM, Bessler M, Sarr MG, Swain JM, Laqua P, Jensen MD, Bantle JP. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA. 2013;309:2240-2249. doi: 10.1001/jama.2013.5835.
11. Adams TD, Davidson LE, Litwin SE, Kolotkin RL, LaMonte MJ, Pendleton RC, Strong MB, Vinik R, Wanner NA, Hopkins PN, Gress RE, Walker JM, Cloward TV, Nuttall RT, Hammoud A, Greenwood JL, Crosby RD, McKinlay R, Simper SC, Smith SC, Hunt SC. Health benefits of gastric bypass surgery after 6 years. JAMA. 2012;308:1122-1131. doi: 10.1001/2012.jama.11164.
12. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L, Nanni G, Pomp A, Castagneto M, Ghirlanda G, Rubino F. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366:1577-1585. doi: 10.1056/NEJMoa1200111.
13. Brethauer SA, Heneghan HM, Eldar S, Gatmaitan P, Huang H, Kashyap S, Gornik HL, Kirwan JP, Schauer PR. Early effects of gastric bypass on endothelial function, inflammation, and cardiovascular risk in obese patients. Surg Endosc. 2011;25:2650-2659. doi: 10.1007/s00464-011-1620-6.
14. Faria G, Preto J, da Costa EL, Guimarães JT, Calhau C, Taveira-Gomes A. Acute improvement in insulin resistance after laparoscopic Roux-en-Y gastric bypass: is 3 days enough to correct insulin metabolism? Obes Surg. 2013;23:103-110. doi: 10.1007/s11695-012-0803-0.
15. Laferrère B, Reilly D, Arias S, Swerdlow N, Gorroochurn P, Bawa B, Bose M, Teixeira J, Stevens RD, Wenner BR, Bain JR, Muehlbauer MJ, Haqq A, Lien L, Shah SH, Svetkey LP, Newgard CB. Differential metabolic impact of gastric bypass surgery versus dietary intervention in obese diabetic subjects despite identical weight loss. Sci Transl Med. 2011;3:80re2. doi: 10.1126/scitranslmed.3002043.
16. Plum L, Ahmed L, Febres G, Bessler M, Inabnet W, Kunreuther E, McMahon DJ, Korner J. Comparison of glucostatic parameters after hypocaloric diet or bariatric surgery and equivalent weight loss. Obesity (Silver Spring). 2011;19:2149-2157. doi: 10.1038/oby.2011.134.
17. Quercia I, Dutia R, Kotler DP, Belsley S, Laferrère B. Gastrointestinal changes after bariatric surgery. Diabetes Metab. 2014;40:87-94. doi: 10.1016/j.diabet.2013.11.003.
18. Laferrère B, Teixeira J, McGinty J, Tran H, Egger JR, Colarusso A, Kovack B, Bawa B, Koshy N, Lee H, Yapp K, Olivan B. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93:2479-2485. doi: 10.1210/jc.2007-2851.
19. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17:819-837. doi: 10.1016/j.cmet.2013.04.008.
20. Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, Aronne L; NN8022-1923 Investigators. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013;37:1443-1451. doi: 10.1038/ijo.2013.120.
21. Anagnostis P, Athyros VG, Adamidou F, Panagiotou A, Kita M, Karagiannis A, Mikhailidis DP. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes Metab. 2011;13:302-312. doi: 10.1111/j.1463-1326.2010.01345.x.
22. Bueter M, Abegg K, Seyfried F, Lutz TA, le Roux CW. Roux-en-Y gastric bypass operation in rats. J Vis Exp. 2012:e3940.
23. Osto E, Matter CM, Kouroedov A, Malinski T, Bachschmid M, Camici GG, Kilic U, Stallmach T, Boren J, Iliceto S, Lüscher TF, Cosentino F. c-Jun N-terminal kinase 2 deficiency protects against hypercholesterolemia-induced endothelial dysfunction and oxidative stress. Circulation. 2008;118:2073-2080. doi: 10.1161/CIRCULATIONAHA.108.765032.
24. Erdogdu O, Eriksson L, Xu H, Sjöholm A, Zhang Q, Nyström T. Exendin-4 protects endothelial cells from lipoapoptosis by PKA, PI3K, eNOS, p38 MAPK, and JNK pathways. J Mol Endocrinol. 2013;50:229-241. doi: 10.1530/JME-12-0166.
25. Weber M, Müller MK, Bucher T, Wildi S, Dindo D, Horber F, Hauser R, Clavien PA. Laparoscopic gastric bypass is superior to laparoscopic gastric banding for treatment of morbid obesity. Ann Surg. 2004;240:975-982.
26. Baron AD. Insulin resistance and vascular function. J Diabetes Complications. 2002;16:92-102.
27. Rask-Madsen C, Li Q, Freund B, Feather D, Abramov R, Wu IH, Chen K, Yamamoto-Hiraoka J, Goldenbogen J, Sotiropoulos KB, Clermont A, Geraldes P, Dall'Osso C, Wagers AJ, Huang PL, Rekhter M, Scalia R, Kahn CR, King GL. Loss of insulin signaling in vascular endothelial cells accelerates atherosclerosis in apolipoprotein E null mice. Cell Metab. 2010;11:379-389. doi: 10.1016/j.cmet.2010.03.013.
28. Zhang L, Yang M, Ren H, Hu H, Boden G, Li L, Yang G. GLP-1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c-JNK. Liver Int. 2013;33:794-804. doi: 10.1111/liv.12120.
29. Hirosumi J, Tuncman G, Chang L, Görgün CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS. A central role for JNK in obesity and insulin resistance. Nature. 2002;420:333-336. doi: 10.1038/nature01137.
30. Fleming I, Fisslthaler B, Dimmeler S, Kemp BE, Busse R. Phosphorylation of Thr(495) regulates Ca(2+)/calmodulin-dependent endothelial nitric oxide synthase activity. Circ Res. 2001;88:E68-E75.
31. Galougahi KK, Liu CC, Gentile C, Kok C, Nunez A, Garcia A, Fry NA, Davies MJ, Hawkins CL, Rasmussen HH, Figtree GA. Glutathionylation mediates angiotensin II-induced eNOS uncoupling, amplifying NADPH oxidase-dependent endothelial dysfunction. J Am Heart Assoc. 2014;3:e000731. doi: 10.1161/JAHA.113.000731.
32. Sivertsen J, Rosenmeier J, Holst JJ, Vilsbøll T. The effect of glucagon-like peptide 1 on cardiovascular risk. Nat Rev Cardiol. 2012;9:209-222. doi: 10.1038/nrcardio.2011.211.
33. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008;117:2340-2350. doi: 10.1161/CIRCULATIONAHA.107.739938.
34. Green BD, Hand KV, Dougan JE, McDonnell BM, Cassidy RS, Grieve DJ. GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP. Arch Biochem Biophys. 2008;478:136-142. doi: 10.1016/j.abb.2008.08.001.
35. Nyström T, Gonon AT, Sjöholm A, Pernow J. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept. 2005;125:173-177. doi: 10.1016/j.regpep.2004.08.024.
36. Laviola L, Leonardini A, Melchiorre M, Orlando MR, Peschechera A, Bortone A, Paparella D, Natalicchio A, Perrini S, Giorgino F. Glucagon-like peptide-1 counteracts oxidative stress-dependent apoptosis of human cardiac progenitor cells by inhibiting the activation of the c-Jun N-terminal protein kinase signaling pathway. Endocrinology. 2012;153:5770-5781. doi: 10.1210/en.2012-1461.
37. Noyan-Ashraf MH, Shikatani EA, Schuiki I, Mukovozov I, Wu J, Li RK, Volchuk A, Robinson LA, Billia F, Drucker DJ, Husain M. A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity. Circulation. 2013;127:74-85. doi: 10.1161/CIRCULATIONAHA.112.091215.
38. Nyström T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahrén B, Sjöholm A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004;287:E1209-E1215. doi: 10.1152/ajpendo.00237.2004.
39. Brolin RE, Bradley LJ, Wilson AC, Cody RP. Lipid risk profile and weight stability after gastric restrictive operations for morbid obesity. J Gastrointest Surg. 2000;4:464-469.
40. Riwanto M, Rohrer L, Roschitzki B, Besler C, Mocharla P, Mueller M, Perisa D, Heinrich K, Altwegg L, von Eckardstein A, Lüscher TF, Landmesser U. Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling. Circulation. 2013;127:891-904. doi: 10.1161/CIRCULATIONAHA.112.108753.
41. Mahley RW, Weisgraber KH, Innerarity T, Brewer HB Jr, Assmann G. Swine lipoproteins and atherosclerosis: changes in the plasma lipoproteins and apoproteins induced by cholesterol feeding. Biochemistry. 1975;14:2817-2823.
42. Xiao C, Dash S, Lewis GF. Mechanisms of incretin effects on plasma lipids and implications for the cardiovascular system. Cardiovasc Hematol Agents Med Chem. 2012;10:289-294.
43. Matsuo Y, Oberbach A, Till H, Inge TH, Wabitsch M, Moss A, Jehmlich N, Völker U, Müller U, Siegfried W, Kanesawa N, Kurabayashi M, Schuler G, Linke A, Adams V. Impaired HDL function in obese adolescents: impact of lifestyle intervention and bariatric surgery. Obesity (Silver Spring). 2013;21:E687-E695. doi: 10.1002/oby.20538.
44. Aron-Wisnewsky J, Julia Z, Poitou C, Bouillot JL, Basdevant A, Chapman MJ, Clement K, Guerin M. Effect of bariatric surgery-induced weight loss on SR-BI-, ABCG1-, and ABCA1-mediated cellular cholesterol efflux in obese women. J Clin Endocrinol Metab. 2011;96:1151-1159. doi: 10.1210/jc.2010-2378.
45. Aicher BO, Haser EK, Freeman LA, Carnie AV, Stonik JA, Wang X, Remaley AT, Kato GJ, Cannon RO 3rd. Diet-induced weight loss in overweight or obese women and changes in high-density lipoprotein levels and function. Obesity (Silver Spring). 2012;20:2057-2062. doi: 10.1038/oby.2012.56.
46. Ahmad NN, Pfalzer A, Kaplan LM. Roux-en-Y gastric bypass normalizes the blunted postprandial bile acid excursion associated with obesity. Int J Obes (Lond). 2013;37:1553-1559. doi: 10.1038/ijo.2013.38.
47. Kida T, Tsubosaka Y, Hori M, Ozaki H, Murata T. Bile acid receptor TGR5 agonism induces NO production and reduces monocyte adhesion in vascular endothelial cells. Arterioscler Thromb Vasc Biol. 2013;33:1663-1669. doi: 10.1161/ATVBAHA.113.301565.